Viking Therapeutics (NASDAQ: VKTX) is a clinical-stage bio-therapeutics company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. The company’s lead clinical program is VK5211, in phase II development for the treatment and prevention of lean body mass loss in patients who have undergone hip fracture surgery; and VK2809, entering phase II development for hypercholesterolemia and fatty liver disease. Viking is also developing novel and selective agonists of the thyroid beta receptor for adrenoleukodystrophy, as well as two earlier-stage programs targeting metabolic diseases and anemia. For more information, visit the company’s website at www.vikingtherapeutics.com